$KZIA News
Last published 2d ago
- 2d agoKZIAKAZIA THERAPEUTICS LIMITED (KZIA) at GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - KAZIA THERAPEUTICS LTDEarnings Call TranscriptsI am very pleased to be joined today with Kaseya Therapeutics. My name is Paul. I'm a biotech analyst with Guggenheim, and today I have John Friend, CEO of Kasey. John, welcome. Thanks, Paul. Appreciate it. So maybe to g
- 2d agoKZIAKAZIA THERAPEUTICS LIMITED (KZIA) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - KAZIA THERAPEUTICS LTDEarnings Call TranscriptsI am very pleased to be joined today with Kaseya Therapeutics. My name is Paul. I'm a biotech analyst with Guggenheim, and today I have John Friend, CEO of Kasey. John, welcome. Thanks, Paul. Appreciate it. So maybe to g
- 1w agoKZIAKazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation ConferencePR NewswireSYDNEY, Oct. 29, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome
- 1mo agoKZIAKazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure DisordersPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology,...
- 2mo agoKZIAKazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain CancerPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively ...
- 2mo agoKZIAKazia Therapeutics Corporate Update Call - KAZIA THERAPEUTICS LTDEarnings Call TranscriptsGood morning, and welcome to CASIA Therapeutics Corporate Update Call. All participants are currently in a listen-only mode. Following the prepared remarks, we'll open the line for questions. Please note that today's cal
- 2mo agoKZIAKazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to ImmunotherapyPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology,...
- 2mo agoKZIAKazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast CancerPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively ...
- 2mo agoKZIAKazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public OfferingPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively ...
- 2mo agoKZIAKazia Therapeutics Limited Announces Pricing of Up to $120 Million Public OfferingPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively ...
- 2mo agoKZIAKazia Therapeutics Limited Announces Proposed Public OfferingPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively ...
- 2mo agoKZIAKazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast CancerPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively ...
- 3mo agoKZIAKazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast CancerGlobeNewswireSYDNEY, July 28, 2026 (GLOBE NEWSWIRE) -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology company developing therapies that reprogram cancer biology, restore anti-tumor immunity and
- 5mo agoBNTXIBRXKZIANTHIThe Multi-Billion-Dollar Search for Better Glioblastoma TreatmentsGlobeNewswireDENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted
- 5mo agoKZIAKazia Therapeutics Appoints James Levine as Chief Financial OfficerPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies...
- 5mo agoKZIAKazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast CancerPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram...
- 7mo agoKZIAKazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology PlatformPR NewswireKazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today...
- 7mo agoKZIAKazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development PlatformPR NewswireKazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment...
- 9mo agoKZIAKazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)PR NewswireKazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today...
- 9mo agoKZIAKazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast CancerPR NewswireKazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with...
- 10mo agoKZIAKazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-EndPR NewswireKazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, John Friend, MD, will be in San Francisco next week to...
- 10mo agoONCYBCTXGLSICTOR+1How $594B in Precision Tech is Cracking the Metastatic Cancer CodePR NewswireThe global cancer drugs market is surging toward $594.3 billion by 2035 as high-tech immunotherapies begin to replace traditional chemotherapy[1]....
- 10mo agoKZIAKazia Therapeutics Regains Full Nasdaq Listing CompliancePR NewswireKazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA), a clinical-stage oncology company focused on developing innovative therapies...
- 11mo agoKZIAKazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+PR NewswireKazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA) today announced new data from two presentations at the 2025 San Antonio Breast...
- 11mo agoKZIAKazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity SecuritiesPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities...
- 11mo agoKZIAKazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory StrategyPR NewswireKazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative ...
- 1y agoKZIAKazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunnerPR NewswireKazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food ...
- 1y agoKZIAKazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader ProgramPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing...
- 1y agoKZIAKazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy RegimenPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today reported a substantial reduction in tumor burden from...
- 1y agoKZIAKazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMGPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company developing innovative therapies for brain cancers, today announced...
- 1y agoKZIAKazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib MonotherapyPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research...
- 1y agoKZIAKazia Therapeutics Announces $2 Million Private Placement at Premium to MarketPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities...
- 1y agoONCYKZIAIMRXNUVB+1Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step UpPR NewswireUSA News Group News Commentary – Cancer rates are rising everywhere, but more dramatically in some places. According to a new analysis of CDC data,...
- 1y agoKZIAKazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b TrialPR NewswireKazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination...
- 1y agoKZIAKazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)PR NewswireKazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics, today announced...
- 1y agoKZIAKazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast CancerPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing innovative therapies for...
- 1y agoKZIAKazia Therapeutics Highlights Recent Progress and Provides Business UpdatePR NewswireKazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced a summary of its...
- 1y agoKZIAKazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for CantrixilPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced the sale of all...
- 1y agoKZIAKazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's DiseasePR NewswireKazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced a research grant...
- 1y agoKZIAKazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancerPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of...
- 1y agoKZIAKazia Therapeutics Announces Closing of $2.0 Million Registered Direct OfferingPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has...
- 1y agoKZIAKazia Therapeutics Announces $2.0 Million Registered Direct OfferingPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has...
- 1y agoKZIAKazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDAPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for the...
- 1y agoKZIAKazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer SymposiumPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development, announced that data from two abstracts will be presented at the San...
- 2y agoKZIAKazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma MultiformePR NewswireKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced that the U.S. Food and Drug Administration (FDA)...
- 2y agoONCYHOLXNVSKZIA+1Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young WomenPR NewswireWith every October, breast cancer awareness surges thanks to very effective campaigns and new developments in breast cancer treatment. However, this...
- 2y agoKZIAKazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual MeetingPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced the presentation of data from a Phase I study...
- 2y agoKZIAKazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research SymposiumPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting ...
- 2y agoKZIAKAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFERPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that an agreement has been executed...
- 2y agoKZIAKazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in GlioblastomaPR NewswireKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce results from GBM-AGILE, a phase...